Shatavari Supplement for Hot Flashes and Menopausal Symptoms

This study is looking at whether a daily nutritional supplement called Shatavari Root Extract can help reduce hot flashes and other symptoms of menopause. Researchers want to see if this supplement can lower how often and how severe your hot flashes are, and if it improves other common menopausal symptoms. You might be able to join if you are a woman between 40 and 60 years old, have gone through menopause, and experience bothersome hot flashes. The study will compare the Shatavari Root Extract to a placebo (a capsule with no active ingredients) over 30 days to see if it makes a difference. The main goal is to see if your hot flash score (frequency multiplied by severity) improves after 30 days.

Study design
This is a randomized, double-blind, placebo-controlled study with two groups, involving 44 participants. This means you would be randomly assigned to receive either the Shatavari Root Extract or a placebo, and neither you nor the study staff would know which one you are taking.
What's involved
You would take either the supplement or a placebo daily for 30 days. You would also track your hot flashes daily using an online survey and complete a symptom questionnaire at the beginning and end of the study.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome for hot flashes is measured at 30 days, which is the end of the intervention period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06939868

Effect of a Cepham Supplement on Hot Flashes and Menopausal Symptoms in Postmenopausal Women

Not Yet Recruiting
NAAges 40–60InterventionalTreatment
Jacksonville University
~44 participants
Updated 2025-04-23 on ClinicalTrials.gov
What's tested:Shatavari Root Extract, oral capsule

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Composite hot flash score: Frequency × Severity
Measured over 30 days
D008593
1 sites across 1 states
Florida1
  • Heather A Hausenblas, PhD · PRINCIPAL_INVESTIGATOR · Jacksonville University

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adult women aged 40-60 years.
Menopause Rating Scale score: (a) GE 14 and (b) score of 3 or 4 (severe to very severe) for hot flashes (Blumel et al., 2018).

Exclusion

Current use of hormone therapy or other medications known to affect hot flashes.
Significant comorbidities that may interfere with study participation.
  • Composite hot flash score: Frequency × Severity30 days

    Frequency: Total number of hot flashes experienced that day. Hot Flash Severity: Rating of hot flashes on a 7-point severity scale (0 = none, 1 = very mild, 2 = mild, 3 = mild/moderate, 4 = moderate, 5 = severe, 6 = very severe)